Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2017-11-01
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT03329248
- Locations
- πΊπΈ
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma
- Conditions
- Lymphoblastic LeukemiaLymphoblastic Lymphoma
- Interventions
- First Posted Date
- 2017-11-01
- Last Posted Date
- 2023-07-21
- Lead Sponsor
- Emory University
- Target Recruit Count
- 8
- Registration Number
- NCT03328104
- Locations
- πΊπΈ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
πΊπΈChildren's Healthcare of Atlanta, Atlanta, Georgia, United States
πΊπΈCincinnati Children's Hospital, Cincinnati, Ohio, United States
Study of BCMA CAR-T in Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2017-10-26
- Last Posted Date
- 2017-12-29
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT03322735
- Locations
- π¨π³
Cancer Hospital Affiliate to Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
- Conditions
- Peripheral T-cell Lymphoma
- Interventions
- First Posted Date
- 2017-10-26
- Last Posted Date
- 2017-10-26
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 102
- Registration Number
- NCT03321890
- Locations
- π¨π³
Department of Medical Oncology,Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer
- Conditions
- COL6A3 PositiveHLA-A*0201 Positive Cells PresentRecurrent Ovarian CarcinomaPRAME Positive
- Interventions
- Biological: AldesleukinDrug: CD8-Positive T-LymphocyteDrug: CyclophosphamideProcedure: LeukapheresisBiological: Utomilumab
- First Posted Date
- 2017-10-24
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 5
- Registration Number
- NCT03318900
- Locations
- πΊπΈ
M D Anderson Cancer Center, Houston, Texas, United States
Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2017-10-24
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 17
- Registration Number
- NCT03318861
- Locations
- πΊπΈ
H. Lee Moffitt Cancer Center, Tampa, Florida, United States
πΊπΈMemorial Sloan Kettering Cancer Center, New York, New York, United States
πΊπΈDavid Geffen School of Medicine at UCLA, Los Angeles, California, United States
Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Conditions
- Acute Myeloid LeukemiaRelapsed/Refractory Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2017-10-23
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 5
- Registration Number
- NCT03318016
- Locations
- πΊπΈ
University of Colorado Denver, Aurora, Colorado, United States
Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis
- Conditions
- IDH1 Gene MutationPlasma Cell MyelomaSecondary MyelofibrosisASXL1 Gene MutationEZH2 Gene MutationPrimary MyelofibrosisAnemiaIDH2 Gene MutationRecurrent Plasma Cell MyelomaThrombocytopenia
- Interventions
- Drug: BusulfanDrug: CyclophosphamideDrug: FludarabineProcedure: Hematopoietic Cell TransplantationOther: Laboratory Biomarker Analysis
- First Posted Date
- 2017-10-06
- Last Posted Date
- 2022-05-05
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 6
- Registration Number
- NCT03303950
- Locations
- πΊπΈ
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
- Conditions
- B Cell LeukemiaHepatocellular CarcinomaAdenocarcinoma of Esophagogastric JunctionB Cell LymphomaMyelomaPancreatic Carcinoma
- Interventions
- Genetic: CAR-CD19 T cellGenetic: CAR-BCMA T cellGenetic: CAR-GPC3 T cellGenetic: CAR-CLD18 T cellDrug: FludarabineDrug: Cyclophosphamide
- First Posted Date
- 2017-10-05
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Kang YU
- Target Recruit Count
- 18
- Registration Number
- NCT03302403
- Locations
- π¨π³
First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer
- Conditions
- Breast CancerTriple Negative Breast Cancer
- Interventions
- First Posted Date
- 2017-10-04
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 29
- Registration Number
- NCT03301350
- Locations
- πΊπΈ
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
πΊπΈColumbia St. Mary's Cancer Center, Milwaukee, Wisconsin, United States
πΊπΈAspirus Regional Cancer Center Wausau, Wausau, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.